MedTrace Logo

Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery

NCT01069341 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2012-10-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to determine the safety of ranibizumab: a) as a surgical adjunct during cataract surgery in subjects with proliferative diabetic retinopathy (PDR) induced rubeosis and, b) in treatment of proliferative diabetic retinopathy (PDR).

Conditions

  • Rubeosis Iridis
  • Proliferative Diabetic Retinopathy

Interventions

DRUG

Ranibizumab

Intravitreally administered 0.5mg ranibizumab, 3 doses administered monthly.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Bhagat, Neelakshi, M.D., M.P.H.

    lead INDIV

Principal Investigators

  • Neelakshi Bhagat, MD, MPH · NJMS / UMDNJ

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2011-12-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01069341 on ClinicalTrials.gov